(Q44423483)

2 December 2017

Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors (English)

1 reference

2 December 2017

1 reference

3

1 reference

2 December 2017

10

1 reference

2 December 2017

11

1 reference

2 December 2017

13

1 reference

ORCID Public Data File 2021

2 December 2017

1 reference

author name string

P A Zucali

1

1 reference

2 December 2017

M G Ruiz

2

1 reference

2 December 2017

A Destro

4

1 reference

2 December 2017

M Varella-Garcia

5

1 reference

2 December 2017

K Floor

6

1 reference

2 December 2017

G L Ceresoli

7

1 reference

2 December 2017

J A Rodriguez

8

1 reference

2 December 2017

I Garassino

9

1 reference

2 December 2017

A Santoro

12

1 reference

2 December 2017

7 May 2008

1 reference

2 December 2017

1 reference

2 December 2017

19

1 reference

2 December 2017

1605-1612

1 reference

2 December 2017

9

1 reference

Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.

2 December 2017

1 reference

12 December 2020

Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.

1 reference

12 December 2020

Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells.

1 reference

12 December 2020

Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.

1 reference

12 December 2020

The clinical significance of hepatocyte growth factor for non-small cell lung cancer

1 reference

12 December 2020

Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas.

1 reference

12 December 2020

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

1 reference

12 December 2020

Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer

1 reference

12 December 2020

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

12 December 2020

Epithelial-mesenchymal transitions in tumour progression

1 reference

12 December 2020

Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients

1 reference

12 December 2020

Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathwa

1 reference

12 December 2020

Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival

1 reference

12 December 2020

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

12 December 2020

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

12 December 2020

Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells

1 reference

12 December 2020

Overexpression of the met/HGF receptor in renal cell carcinomas

1 reference

12 December 2020

Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF.

1 reference

12 December 2020

Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.

1 reference

12 December 2020

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

12 December 2020

Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study

1 reference

12 December 2020

The Met pathway: master switch and drug target in cancer progression

1 reference

12 December 2020

Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design

1 reference

12 December 2020

Biological and clinical implications of EGFR mutations in lung cancer.

1 reference

12 December 2020

Mitogenic activation, phosphorylation, and nuclear translocation of protein kinase Bbeta

1 reference

12 December 2020

Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity

1 reference

12 December 2020

Identifiers

DOI

10.1093/ANNONC/MDN240

1 reference

2 December 2017

1 reference